ParcelBio: Engineering potent and durable mRNA for in vivo CAR Ts

ParcelBio is aiming to solve the durability problem for in vivo RNA-based CAR Ts by engineering stabilized mRNA to drive longer-lasting, deeper B-cell depletion beyond the current capabilities of linear mRNA or circular RNA designs for autoimmune diseases.

A number of companies are beginning to figure out how to design and dose in vivo CAR Ts to generate response rates that rival or top ex vivo CAR Ts, but there’s debate in the field over whether they will match ex vivo durability. ...